Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Assets

psilocybin (investigator-led)

Region Skane

Molecule class
psilocybin
Mechanism
not_applicable
Phase
Phase 2 recruiting
Indication
anorexia nervosa
Sponsor geography
SE
Next catalyst
None recorded.
IP status
not_applicable

clinicaltrials.govregistryverified 2026-08-24

Registered trials

In the briefing

Issues tagged REGION-SKANE, the owner of this asset.